HOW THE FUND HAS PERFORMED
WHERE THE FUND INVESTS
- Date of launch: 1 May 2010
- Category: Equity
- Type: Large Cap
- AUM(As on 30 November 2021): Rs 33,519 crore
- Benchmark: S&P BSE 100 Total Return Index
WHAT IT COSTS
- NAV (As on 21 December 2021)
- Growth option: Rs 44.73
- IDCW: Rs 19.65
- Minimum Investment: Rs 5,000
- Minimum SIP Amount: Rs 500
- Expense Ratio(As on 31 October 2021) (%): 1.64
- Exit load: For units in excess of 10% of the investment, 1% will be charged for redemption within 365 days
FUND MANAGER: Shreyash Devalkar
Tenure: 5 Year
Top 5 sectors in portfolio (%)
Top 5 stocks in portfolio (%)
Recent portfolio changes
- New Entrants: Sun Pharma, Larsen & Toubro, Mahindra & Mahindra.
- Complete Exits: Tata Steel, Cipla, HDFC Life Insurance Co, Hindalco Industries.
- Increasing allocation: Avenue Supermarts, Bajaj Finserv, Cholamandalam Inv, Gland Pharma, ICICI Bank, Info Edge (India), Kotak Mahindra Bank, Pidilite Inds, TCS, Ultratech Cement, Wipro.
How risky is it?
Source: Value research
Should you buy?
This large-cap fund maintains a strict bias towards quality which sees it run a highly compact portfolio, almost packed with bluechip names. This construct gives it a distinct flavour in a category characterised by indistinguishable funds. The lean portfolio allows the fund to run large positions in top few bets. While its differentiated approach gave it an edge over peers in a highly polarised market until recently. A broad-based market uptick since last year has seen its star fade. However, the fund retains a far superior risk-return profile in its category owing to strong emphasis on downside protection that should help the fund retain outperformance across market cycles.